The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis

被引:49
|
作者
Tehranian, Cedric [1 ]
Fankhauser, Laura [1 ]
Harter, Patrick N. [2 ,3 ,4 ]
Ratcliffe, Colin D. H. [5 ]
Zeiner, Pia S. [2 ,4 ,6 ]
Messmer, Julia M. [1 ,7 ]
Hoffmann, Dirk C. [1 ,7 ]
Frey, Katharina [1 ]
Westphal, Dana [8 ,9 ]
Ronellenfitsch, Michael W. [4 ,6 ]
Sahai, Erik [5 ]
Wick, Wolfgang [1 ,2 ]
Karreman, Matthia A. [1 ,2 ]
Winkler, Frank [1 ,2 ]
机构
[1] German Canc Res Ctr, Clin Cooperat Unit Neurooncol, German Canc Consortium DKTK, INF 280, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Neurol Clin & Natl Ctr Tumor Dis, Heidelberg, Germany
[3] Univ Frankfurt Main, Edinger Inst, Inst Neurol, Frankfurt, Germany
[4] Frankfurt Canc Inst FCI, Frankfurt, Germany
[5] Francis Crick Inst, Tumour Cell Biol Lab, London, England
[6] Univ Frankfurt Main, Senckenberg Inst Neurooncol, Frankfurt, Germany
[7] Heidelberg Univ, Fac Biosci, Heidelberg, Germany
[8] Tech Univ Dresden, Dept Dermatol, Med Fac, Dresden, Germany
[9] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany
基金
英国惠康基金; 英国医学研究理事会;
关键词
brain metastasis; dual PI3K; mTOR inhibition; extravasation; PI3K; Akt; mTOR pathway; tertiary prevention; PI3K PATHWAY; BREAST-CANCER; GROWTH; SURVIVAL; EFFICACY; THERAPY; REVEALS; CROSS;
D O I
10.1093/neuonc/noab159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Brain metastases (BM) are a frequent complication of malignant melanoma (MM), with limited treatment options and poor survival. Prevention of BM could be more effective and better tolerated than treating established BM in various conditions. Methods To investigate the temporospatial dynamics of PI3K/Akt/mTOR (PAM) pathway activation during BM formation and the preventive potential of its inhibition, in vivo molecular imaging with an Akt biosensor was performed, and long-term intravital multiphoton microscopy through a chronic cranial window in mice. Results In vivo molecular imaging revealed invariable PAM pathway activation during the earliest steps of brain colonization. In order to perform a long-term intravascular arrest and to extravasate, circulating MM cells needed to activate their PAM pathway during this process. However, the PAM pathway was quite heterogeneously activated in established human brain metastases, and its inhibition with the brain-penetrant PAM inhibitor GNE-317 resulted in only modest therapeutic effects in mice. In contrast, giving GNE-317 in preventive schedules that included very low doses effectively reduced the growth rate and number of BM in two MM mouse models over time, and led to an overall survival benefit. Longitudinal intravital multiphoton microscopy found that the first, rate-limiting steps of BM formation-permanent intravascular arrest, extravasation, and initial perivascular growth-are most vulnerable to dual PI3K/mTOR inhibition. Conclusion These findings establish a key role of PAM pathway activation for critical steps of early metastatic brain colonization and reveal its pharmacological inhibition as a potent avenue to prevent the formation of clinically relevant BM.
引用
收藏
页码:213 / 225
页数:13
相关论文
共 50 条
  • [41] The PI3K/AKT Pathway as a Target for Cancer Treatment
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 11 - 28
  • [42] Coordinate autophagy and PI3K/Akt/mTOR pathway inhibition enhances cell death in melanoma
    Xie, Xiaoqi
    Mehnert, Janice M.
    White, Eileen P.
    CANCER RESEARCH, 2012, 72
  • [43] Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway
    Hua, Hui
    Zhu, Yu
    Song, Yu-He
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 101 : 115 - 122
  • [44] Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
    Totiger, Tulasigeri M.
    Srinivasan, Supriya
    Jala, Venkatakrishna R.
    Lamichhane, Purushottam
    Dosch, Austin R.
    Gaidarski, Alexander A., III
    Joshi, Chandrashekhar
    Rangappa, Shobith
    Castellanos, Jason
    Vemula, Praveen Kumar
    Chen, Xi
    Kwon, Deukwoo
    Kashikar, Nilesh
    VanSaun, Michael
    Merchant, Nipun B.
    Nagathihalli, Nagaraj S.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 301 - 311
  • [45] The PI3K/Akt/mTOR pathway:: a new therapeutic target in the treatment of acute myeloid leukemia
    Dos Santos, Cedric
    Recher, Christian
    Demur, Cecile
    Payrastre, Bernard
    BULLETIN DU CANCER, 2006, 93 (05) : 445 - 447
  • [46] Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis
    Giacoppo, Sabrina
    Pollastro, Federica
    Grassi, Gianpaolo
    Bramanti, Placido
    Mazzon, Emanuela
    FITOTERAPIA, 2017, 116 : 77 - 84
  • [47] The role of ubiquitination and deubiquitination in PI3K/AKT/mTOR pathway: A potential target for cancer therapy
    Jin, Jiabei
    He, Jian
    Li, Xinming
    Ni, Xiaoqi
    Jin, Xiaofeng
    GENE, 2023, 889
  • [48] Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma
    Nanda, Vashisht G. Y.
    Peng, Weiyi
    Hwu, Patrick
    Davies, Michael A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [49] Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy
    Yothaisong, Supak
    Dokduang, Hasaya
    Techasen, Anchalee
    Namwat, Nisana
    Yongvanit, Puangrat
    Bhudhisawasdi, Vajarabhongsa
    Puapairoj, Anucha
    Riggins, Gregory J.
    Loilome, Watcharin
    TUMOR BIOLOGY, 2013, 34 (06) : 3637 - 3648
  • [50] PI3K/Akt/mTOR - A new target for corneal angiogenesis treatment?
    Adrian Calles, Javier
    Sasore, Temitope
    Lopez-Garcia, Antonio
    Kennedy, Breandan N.
    Diebold, Yolanda
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)